Diagnosis and Treatment of Osteoporosis in Older Adults

Endocrinology and Metabolism Clinics of North America

Volumn 42, Issue 2, 2013, Pages 305-317

  Diab, Dima L ^a   Watts, Nelson B ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Mercy Health Osteoporosis and Bone Health Services   (United States)

Author keywords

Diagnosis; Elderly; Fall prevention; Fractures; Frailty; Older adults; Osteoporosis; Treatment

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DENOSUMAB; ESTROGEN; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; VITAMIN D; ZOLEDRONIC ACID;

AGED; AGING; ASSISTIVE TECHNOLOGY DEVICE; BONE DENSITY; BONE TURNOVER; CALCIUM INTAKE; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG MECHANISM; DRUG MEGADOSE; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; FALLING; FOOD AND DRUG ADMINISTRATION; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; INCIDENCE; MORBIDITY; MORTALITY; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTECTIVE EQUIPMENT; PSYCHOSOCIAL CARE; REVIEW; RISK FACTOR; RISK REDUCTION; SPINE FRACTURE; VITAMIN D DEFICIENCY;

ACCIDENT PREVENTION; AGING; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM, DIETARY; COMBINED MODALITY THERAPY; DIETARY SUPPLEMENTS; HUMANS; MOTOR ACTIVITY; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RISK FACTORS; SOCIAL SUPPORT; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84878119219     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2013.02.007     Document Type: Review

References (78)

1. Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement 2000, 17:1.
2. Bone health and osteoporosis: a report of the Surgeon General. Available at:. Accessed November 30, 2012. http://www.surgeongeneral.gov/library/reports/bonehealth/full_report.pdf.
3. Melton L.J. How many women have osteoporosis now?. J Bone Miner Res 1995, 10:175.
4. Burger H., de Laet C.E., van Daele P.L., et al. Risk factors for increased bone loss in an elderly population: the Rotterdam Study. Am J Epidemiol 1998, 147:871.
5. Schuit S.C., van der Klift M., Weel A.E., et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004, 34:195.
6. Burge R., Dawson-Hughes B., Solomon D.H., et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007, 22:465.
7. Rizzoli R., Bruyere O., Cannata-Andia J.B., et al. Management of osteoporosis in the elderly. Curr Med Res Opin 2009, 25:2373.
8. Kanis J.A., Johnell O., Oden A., et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001, 12:989.
9. Birge S.J. Osteoporotic fractures: a brain or bone disease?. Curr Osteoporos Rep 2008, 6:57.
10. Zimmerman S.I., Girman C.J., Buie V.C., et al. The prevalence of osteoporosis in nursing home residents. Osteoporos Int 1999, 9:151.
11. Rojas-Fernandez C.H., Lapane K.L., MacKnight C., et al. Undertreatment of osteoporosis in residents of nursing homes: population-based study with use of the Systematic Assessment of Geriatric Drug Use via Epidemiology (SAGE) database. Endocr Pract 2002, 8:335.
12. Zimmerman S., Chandler J.M., Hawkes W., et al. Effect of fracture on the health care use of nursing home residents. Arch Intern Med 2002, 162:1502.
13. US Preventive Services Task Force Screening for osteoporosis: US Preventive Services Task Force recommendation statement. Ann Intern Med 2011, 154:356.
14. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Available at:. Accessed November 30, 2012. http://www.nof.org/files/nof/public/content/file/344/upload/159.pdf.
15. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282:637.
16. Hansdottir H., Franzson L., Prestwood K., et al. The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities. J Am Geriatr Soc 2004, 52:779.
17. Chesnut C.H., Silverman S., Andriano K., et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000, 109:267.
18. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535.
19. Hochberg M.C., Thompson D.E., Black D.M., et al. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res 2005, 20:971.
20. Greenspan S.L., Schneider D.L., McClung M.R., et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002, 136:742.
21. McClung M.R., Geusens P., Miller P.D., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001, 344:333.
22. Watts N.B., Josse R.G., Hamdy R.C., et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2003, 88:542.
23. Boonen S., McClung M.R., Eastell R., et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 2004, 52:1832.
24. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799.
25. Boonen S., Orwoll E., Magaziner J., et al. Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc 2011, 59:2084.
26. Boonen S., Black D.M., Colon-Emeric C.S., et al. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 2010, 58:292.
27. Crandall CJ, Newberry SJ, Diamant A, et al. Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report. In: AHRQ comparative effectiveness reviews. Rockville (MD): 2012. Available at:. Accessed November 30, 2012. http://www.ncbi.nlm.nih.gov/books/NBK92566/.
28. Pham A.N., Datta S.K., Weber T.J., et al. Cost-effectiveness of oral bisphosphonates for osteoporosis at different ages and levels of life expectancy. J Am Geriatr Soc 2011, 59:1642.
29. Papapoulos S., Chapurlat R., Libanati C., et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 2012, 27:694.
30. Boonen S., Adachi J.D., Man Z., et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2011, 96:1727.
31. McClung M., Boonen S., Torring O., et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res 2012, 27:211.
32. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434.
33. Boonen S., Marin F., Mellstrom D., et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 2006, 54:782.
34. Curtis J.R., Safford M.M. Management of osteoporosis among the elderly with other chronic medical conditions. Drugs Aging 2012, 29:549.
35. Penning-van Beest F.J., Erkens J.A., Olson M., et al. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin 2008, 24:1337.
36. Papaioannou A., Kennedy C.C., Dolovich L., et al. Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 2007, 24:37.
37. Gold D.T., Silverman S. Review of adherence to medications for the treatment of osteoporosis. Curr Osteoporos Rep 2006, 4:21.
38. Schott A.M., Cormier C., Hans D., et al. How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study. Osteoporos Int 1998, 8:247.
39. Cummings S.R., Nevitt M.C., Browner W.S., et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995, 332:767.
40. Dargent-Molina P., Favier F., Grandjean H., et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet 1996, 348:145.
41. Girman C.J., Chandler J.M., Zimmerman S.I., et al. Prediction of fracture in nursing home residents. J Am Geriatr Soc 2002, 50:1341.
42. Grundstrom A.C., Guse C.E., Layde P.M. Risk factors for falls and fall-related injuries in adults 85 years of age and older. Arch Gerontol Geriatr 2012, 54:421.
43. Gillespie L.D., Robertson M.C., Gillespie W.J., et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2012, (9). CD007146.
44. Waldron N., Hill A.M., Barker A. Falls prevention in older adults-assessment and management. Aust Fam Physician 2012, 41:930.
45. Li F., Harmer P., Fisher K.J., et al. Tai Chi and fall reductions in older adults: a randomized controlled trial. J Gerontol A Biol Sci Med Sci 2005, 60:187.
46. Sherrington C., Whitney J.C., Lord S.R., et al. Effective exercise for the prevention of falls: a systematic review and meta-analysis. J Am Geriatr Soc 2008, 56:2234.
47. Holick M.F. The role of vitamin D for bone health and fracture prevention. Curr Osteoporos Rep 2006, 4:96.
48. Visser M., Deeg D.J., Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 2003, 88:5766.
49. Bischoff-Ferrari H.A., Staehelin H.B. Importance of vitamin D and calcium at older age. Int J Vitam Nutr Res 2008, 78:286.
50. Holick M.F. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006, 81:353.
51. MacLaughlin J., Holick M.F. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest 1985, 76:1536.
52. Bischoff H.A., Stahelin H.B., Dick W., et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 2003, 18:343.
53. Bischoff-Ferrari H.A., Dawson-Hughes B., Willett W.C., et al. Effect of Vitamin D on falls: a meta-analysis. JAMA 2004, 291:1999.
54. Pfeifer M., Begerow B., Minne H.W., et al. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000, 15:1113.
55. Pfeifer M., Begerow B., Minne H.W., et al. Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos Int 2009, 20:315.
56. Trivedi D.P., Doll R., Khaw K.T. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003, 326:469.
57. Bischoff-Ferrari H.A., Willett W.C., Wong J.B., et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005, 293:2257.
58. Bischoff-Ferrari H.A., Willett W.C., Orav E.J., et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012, 367:40.
59. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011, 96:1911.
60. Bischoff-Ferrari H.A. Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv Exp Med Biol 2008, 624:55.
61. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., et al. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab 2012, 97:1153.
62. Chapuy M.C., Arlot M.E., Duboeuf F., et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992, 327:1637.
63. Riggs B.L., O'Fallon W.M., Muhs J., et al. Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women. J Bone Miner Res 1998, 13:168.
64. Storm D., Eslin R., Porter E.S., et al. Calcium supplementation prevents seasonal bone loss and changes in biochemical markers of bone turnover in elderly New England women: a randomized placebo-controlled trial. J Clin Endocrinol Metab 1998, 83:3817.
65. Prentice R.L., Pettinger M.B., Jackson R.D., et al. Health risks and benefits from calcium and vitamin D supplementation: women's health initiative clinical trial and cohort study. Osteoporos Int 2012, 24(2):567-580.
66. Verbrugge F.H., Gielen E., Milisen K., et al. Who should receive calcium and vitamin D supplementation?. Age Ageing 2012, 41:576.
67. Tang B.M., Eslick G.D., Nowson C., et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007, 370:657.
68. Gillespie W.J., Gillespie L.D., Parker M.J. Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev 2010, (6). CD001255.
69. Kannus P., Parkkari J. Hip protectors for preventing hip fracture. JAMA 2007, 298:454.
70. Kannus P., Parkkari J., Niemi S., et al. Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med 2000, 343:1506.
71. Kannus P., Sievanen H., Palvanen M., et al. Prevention of falls and consequent injuries in elderly people. Lancet 2005, 366:1885.
72. Kiel D.P., Magaziner J., Zimmerman S., et al. Efficacy of a hip protector to prevent hip fracture in nursing home residents: the HIP PRO randomized controlled trial. JAMA 2007, 298:413.
73. Gold D.T., Shipp K.M., Lyles K.W. Managing patients with complications of osteoporosis. Endocrinol Metab Clin North Am 1998, 27:485.
74. Gold D.T. Osteoporosis and quality of life psychosocial outcomes and interventions for individual patients. Clin Geriatr Med 2003, 19:271.
75. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1344.
76. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280:2077.
77. Reginster J., Minne H.W., Sorensen O.H., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11:83.
78. Cummings S.R., San Martin J., McClung M.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361:756.